Ignyta

Boundless Bio uncloaks with $46M to pursue extrachromosomal DN

With $46 million, Boundless is using a new understanding of amplification mutatons to create a new class of drugs to fight difficult-to-treat cancers.

Amirah Al Idrus Sep 19, 2019 5:00am

Erasca picks up $42M to target biological drivers of cancer

Dec 18, 2018 9:28am

Roche splashes $1.7B in cash for Ignyta and entrectinib

Dec 22, 2017 4:21am

Ignyta NSCLC durability data set stage for Pfizer fight

Oct 18, 2017 9:26am

ROS1 cancer patients set out to create disease models

Aug 15, 2017 8:55am

Ignyta agrees new terms with Lilly for troubled cancer alliance

Mar 24, 2017 9:29am